Top Markets
Coin of the day
BCAL Diagnostics Limited BCAL Diagnostics Limited

BCAL Diagnostics Limited

BDX
Rank in Stocks #31187
BCAL Diagnostics Limited is a biotechnology firm focused on creating an... BCAL Diagnostics Limited is a biotechnology firm focused on creating an advanced, non-surgical laboratory blood test for the identification of breast cancer. Its flagship product, the BCAL test, is a lipid biomarker-based blood assay designed for potential use in breast cancer prevention strategies, early screening, and ongoing patient monitoring. This in vitro diagnostic (IVD) technology functions by detecting a unique pattern of lipid biomarkers, which are isolated from extracellular vesicles present in a patient's plasma or blood, thereby enabling the diagnosis of breast cancer cells. Established in 2010, the company's main operations are based in Sydney, Australia.
Share Price
$0.03808538
Market Cap
$14.04M
Change (1 day)
-3.57%
Change (1 year)
6.63%
Country
AU
Trade BCAL Diagnostics Limited (BDX)

Category

P/S ratio for BCAL Diagnostics Limited (BDX)
P/S ratio as of 2026 TTM: 0
According to BCAL Diagnostics Limited latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for BCAL Diagnostics Limited from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
4.72 -
US
5.67 -
US
- -
CN
16.40 -
US
9.55 -
US